Back to search
Metastatic Breast Cancer, HER2 Negative Primary Tumor
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Breast Cancer, HER2 Negative Primary Tumor trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Breast Cancer, HER2 Negative Primary Tumor trials you may qualify forThis ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients w…
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participa…
This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in pat…
This is a multi-center biomarkers study aiming to prospectively collect biological samples from patients with ER+ and HER2-negative metastatic breast cancer, wh…
This phase II trial studies how well genetic testing works in predicting tumor response in patients with stage I-III HER2 negative invasive breast cancer. Genet…
This phase Ib/II trial studies the side effects and best dose of olaparib and vistusertib (AZD2014) or olaparib and capivasertib (AZD5363) when given together i…